| Literature DB >> 35204856 |
Ju Hee Kim1, Hey-Sung Baek1, Eun Kyo Ha2, Hye Ryung Cha3, Seung Won Lee3,4, Man Yong Han5.
Abstract
OBJECTIVE: The objective of this study was to analyze the effect of consuming formula powder prepared with tap water or purified water during the first 4 to 6 months of life on the subsequent development of irritable bowel syndrome (IBS). STUDY DESIGN ANDEntities:
Keywords: gut microbiota; irritable bowel syndrome; purified water; tap water
Year: 2022 PMID: 35204856 PMCID: PMC8869972 DOI: 10.3390/children9020135
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Figure 1Enrollment, assessment of eligibility, and weighting of study participants. Abbreviations: N, number; NICKs-2008, the National Investigation of Birth Cohort in Korea; ICU, intensive care unit; ICD, International Classification of Disease.
Basic sociodemographic characteristics of the participants a.
| Sociodemographic | Observed Data (N = 74,006) | Weighted Data (N = 146,706) b | ||||
|---|---|---|---|---|---|---|
| N (%) c | Standardized Difference | N (%) c | Standardized Difference | |||
| Tap Water d | Purified Water e | Tap Water d | Purified Water e | |||
| (N = 28,850) | (N = 45,156) | (N = 73,355) | (N = 73,351) | |||
| Sex | ||||||
| Male | 15,156 (52.5) | 23,704 (52.5) | 0.1 | 38,532 (52.5) | 38,506 (52.5) | 0.1 |
| Female | 13,694 (47.5) | 21,452 (47.5) | 34,824 (47.5) | 34,845 (47.5) | ||
| Residence at birth g | ||||||
| Seoul | 6625 (23.0) | 10,615 (23.5) | 1.3 | 17,115 (23.3) | 17,089 (23.3) | 0.0 |
| Metropolitan | 6732 (23.3) | 11,165 (24.7) | 3.3 | 17,715 (24.2) | 17,737 (24.2) | 0.1 |
| Urban | 11,614 (40.3) | 18,361 (40.7) | 0.8 | 29,715 (40.5) | 29,712 (40.5) | 0.1 |
| Rural | 3619 (12.5) | 4620 (10.2) | 7.3 | 8162 (11.1) | 8164 (11.1) | 0.0 |
| Birth weight, kg (SD) h | 3.22 (0.32) | 3.22 (0.32) | 1.5 | 3.22 (0.51) | 3.22 (0.41) | 0.0 |
| Income quintile i | ||||||
| 1 (Lowest) | 2300 (8.0) | 3384 (7.5) | 1.8 | 5643 (7.7) | 5636 (7.7) | 0.0 |
| 2 | 4557 (15.8) | 6177 (13.7) | 6.0 | 10,628 (14.5) | 10,632 (14.5) | 0.0 |
| 3 (Middle) | 8215 (28.5) | 11,238 (24.5) | 8.1 | 19,316 (26.3) | 19,305 (26.3) | 0.0 |
| 4 | 9141 (31.7) | 14,374 (31.8) | 0.3 | 23,287 (31.7) | 23,297 (31.8) | 0.0 |
| 5 (Highest) | 3757 (13.0) | 8399 (18.6) | 15.3 | 12,044 (16.4) | 12,042 (16.4) | 0.0 |
| Birth year | ||||||
| 2008 | 13,140 (45.5) | 21,566 (47.8) | 4.4 | 34,291 (46.7) | 34,318 (46.8) | 0.1 |
| 2009 | 15,710 (54.5) | 23,590 (52.2) | 39,064 (53.3) | 39,033 (53.2) | ||
Abbreviations: N, Number; SD, standard deviation. a Unless otherwise specified, baseline characteristics were assessed on the birth date of the patient. b Weighted using inverse probability of exposure weighting based on the propensity score. The propensity score was estimated using multivariable logistic regression with 103 previous covariates, as defined in Table S2 in the Supplementary Materials. Participants in the reference group were weighted as (propensity score)/(1 − propensity score). This method produces a weighted pseudo-sample of participants in the reference group with the same distribution of measured covariates as the exposure group. c Results are reported as N (%) unless otherwise indicated. d The tap water (reference) group consisted of children who mainly consumed formula powder prepared with tap water during the first 4 to 6 months of life. e The purified water group consisted of children who mainly consumed formula powder prepared with purified water during the first 4 to 6 months of life. f Differences greater than 10% were interpreted as meaningful differences. All standardized differences in the cohort values were <0.05. g Metropolitan areas were defined as six metropolitan cities (Busan, Incheon, Gwangju, Daejeon, Daegu, and Ulsan), urban areas as cities, and rural areas as non-city areas. Missing data of observed data: tap water = 260, purified water = 395; missing data of weighted data: tap water = 646, purified water = 649. h Obtained from the 1st National Health Screening Program of Infants and Children at 4–6 months of birth. i Income status was categorized into the quintile of insurance premium at birth. Missing data of observed data: tap water = 880, purified water = 1584; missing data of weighted data: tap water = 2438, purified water = 2440.
Basic clinical characteristics of the participants a.
| Clinical | Observed Data (N = 74,006) | Weighted Data (N = 146,706) b | ||||
|---|---|---|---|---|---|---|
| N (%) c | Standardized Difference | N (%) c | Standardized Difference | |||
| Tap Water d | Purified Water e | Tap Water d | Purified Water e | |||
| (N = 28,850) | (N = 45,156) | (N = 73,355) | (N = 73,351) | |||
| Hospital utilization within six months of age | ||||||
| Visiting to pediatricians | 28,178 (97.7) | 44,116 (97.7) | 0.2 | 71,666 (97.7) | 71,658 (97.7) | 0.0 |
| Visiting ER | 2281 (7.9) | 3789 (8.4) | 1.7 | 6030 (8.2) | 6010 (8.2) | 0.0 |
| Hospitalization | 5150 (17.9) | 8419 (18.6) | 2.1 | 13,452 (18.3) | 13,458 (18.3) | 0.0 |
| Certain conditions (ICD-10 codes) originating in the perinatal period | ||||||
| Respiratory and cardiovascular disorders specific to the perinatal period | 1199 (4.2) | 1793 (4.0) | 0.9 | 2974 (4.1) | 2967 (4.1) | 0.0 |
| Infections specific to the perinatal period | 4066 (14.1) | 6176 (13.7) | 1.2 | 10,152 (13.8) | 10,146 (13.8) | 0.0 |
| Hemorrhagic and hematological disorders of fetuses and newborns | 8051 (27.9) | 12,608 (27.9) | 0.0 | 20,483 (27.9) | 20,484 (27.9) | 0.0 |
| Prevalent diseases (ICD-10 codes) diagnosed within six months of age | ||||||
| Viral intestinal infection, unspecified | 9741 (2.7) | 459 (5.2) | 12.9 | 10,064 (2.8) | 11,772 (3.3) | 0.6 |
| Other and unspecified gastroenteritis and colitis of infectious origin | 18,362 (5.1) | 707 (8.0) | 11.9 | 18,802 (5.2) | 20,941 (5.8) | 0.7 |
| Gastroenteritis and colitis of unspecified origin | 20,055 (5.6) | 781 (8.9) | 12.8 | 20,541 (5.7) | 22,505 (6.3) | 0.8 |
| Conjunctivitis, unspecified | 14,776 (4.1) | 397 (4.5) | 2.0 | 14,961 (4.1) | 14,662 (4.1) | 0.4 |
| Otitis media, unspecified | 7989 (2.2) | 204 (2.3) | 0.7 | 8058 (2.2) | 7869 (2.2) | 0.2 |
| Acute nasopharyngitis | 104,381 (29.0) | 3,056 (34.8) | 12.4 | 105,974 (29.2) | 107,273 (29.8) | 0.1 |
| Acute sinusitis, unspecified | 12,585 (3.5) | 304 (3.5) | 0.2 | 12,707 (3.5) | 12,261 (3.4) | 0.4 |
| Acute pharyngitis | 37,920 (10.5) | 1103 (12.6) | 6.3 | 38,483 (10.6) | 39,901 (11.1) | 0.6 |
| Acute tonsillitis, unspecified | 18,232 (5.1) | 464 (5.3) | 1.0 | 18,411 (5.1) | 18,064 (5.0) | 0.1 |
| Other acute upper respiratory infections of multiple sites | 9292 (2.6) | 265 (3.0) | 2.6 | 9427 (2.6) | 9916 (2.8) | 0.3 |
| Acute upper respiratory infection, unspecified | 81,665 (22.7) | 2198 (25.0) | 5.4 | 82,711 (22.8) | 84,377 (23.4) | 0.5 |
| Pneumonia, unspecified | 9496 (2.6) | 225 (2.6) | 0.5 | 9569 (2.6) | 10,044 (2.8) | 0.6 |
| Acute bronchitis | 66,304 (18.4) | 1,634 (18.6) | 0.4 | 66,995 (18.4) | 66,559 (18.5) | 0.7 |
| Acute bronchiolitis | 48,798 (13.6) | 1,129 (12.8) | 2.1 | 49,176 (13.5) | 50,601 (14.1) | 0.7 |
| Gastro-esophageal reflux disease without esophagitis | 8416 (2.3) | 333 (3.8) | 8.4 | 8617 (2.4) | 8590 (2.3) | 0.4 |
| Functional dyspepsia | 7635 (2.1) | 315 (3.6) | 8.8 | 7834 (2.2) | 8289 (5.1) | 0.2 |
| Noninfective gastroenteritis and colitis, unspecified | 16,372 (4.6) | 561 (6.4) | 8.1 | 16,709 (4.6) | 18,306 (5.1) | 0.8 |
| Constipation | 15,365 (4.3) | 574 (6.5) | 10.0 | 15,699 (4.3) | 16,272 (4.5) | 0.7 |
| Functional diarrhea | 5223 (1.5) | 205 (2.3) | 6.5 | 5360 (1.5) | 5375 (1.5) | 0.0 |
| Functional intestinal disorder, unspecified | 10,060 (2.8) | 357 (4.1) | 7.0 | 10,248 (2.8) | 10,274 (2.9) | 0.1 |
| Nausea and vomiting | 10,334 (2.9) | 495 (5.6) | 13.7 | 10,699 (2.9) | 11,869 (3.3) | 0.5 |
| Fever, unspecified | 18,237 (5.1) | 524 (6.0) | 3.9 | 18,507 (5.1) | 21,194 (5.9) | 0.1 |
| Drug (drug classification code) used within six months of age | ||||||
| Antipyretics | 17,166 (59.5) | 28,027 (62.1) | 5.3 | 44,808 (61.1) | 44,796 (61.1) | 0.0 |
| Antihistamine | 19,707 (68.3) | 32,541 (72.1) | 8.2 | 51,843 (70.7) | 51,817 (70.6) | 0.0 |
| Digestive anti-ulcer drug | 524 (1.8) | 884 (2.0) | 1.0 | 1384 (1.9) | 1390 (1.9) | 0.0 |
| Antiacid drug | 313 (1.1) | 558 (1.2) | 1.4 | 858 (1.2) | 861 (1.2) | 0.0 |
| Probiotics | 20,061 (69.5) | 32,396 (71.7) | 4.8 | 51,976 (70.9) | 51,983 (70.2) | 0.0 |
| Laxative drug | 39 (0.1) | 76 (0.2) | 0.9 | 114 (0.2) | 114 (0.2) | 0.0 |
| Other digestive system drugs | 11,080 (38.4) | 17,939 (39.7) | 2.7 | 28,760 (39.2) | 28,760 (39.2) | 0.0 |
| Steroid | 3481 (12.1) | 6,199 (13.7) | 5.0 | 9588 (13.1) | 9592 (13.1) | 0.0 |
Abbreviations: N, Number; ICD, International Classification of Diseases; ER, emergency room; ICU, intensive care unit. a Unless otherwise specified, all baseline characteristics were assessed in the first six months of age of the participants. b Weighted using inverse probability of exposure weighting based on the propensity score. The propensity score was estimated using multivariable logistic regression with 103 previous covariates, as defined in Table S2 in the Supplementary Materials. Participants in the reference group were weighted as (propensity score)/(1 − propensity score). This method produces a weighted pseudo-sample of participants in the reference group with the same distribution of measured covariates as the exposure group. c Results are reported as N (%) unless otherwise indicated. d The tap water (reference) group consisted of children who mainly consumed formula powder prepared with tap water during the first 4 to 6 months of life. e The purified water group consisted of children who mainly consumed formula powder prepared with purified water during the first 4 to 6 months of life. f Differences greater than 10% were interpreted as meaningful differences. All standardized differences in the cohort values were <0.05.
Risk of irritable bowel syndrome a.
| Observed Data (N = 74,006) | Weighted Data (N = 146,706) b | HR | ||||
|---|---|---|---|---|---|---|
| N (%) | N (%) | |||||
| Tap water c | Purified water d | Tap water c | Purified water d | |||
| (N = 28,850) | (N = 45,156) | (N = 73,355) | (N = 73,351) | |||
| Main outcome | ||||||
| IBS f | 4380 (15.2) | 7216 (16.0) | 11,197 (15.3) | 11,721 (16.0) | 1.051 | <0.01 |
| Sensitivity analysis | ||||||
| IBS-1 g | 2787 (9.66) | 4686 (10.4) | 7176 (9.8) | 7598 (10.4) | 1.062 | 0.01 |
| IBS-2 h | 3059 (10.6) | 5103 (11.3) | 7827 (10.7) | 8277 (11.3) | 1.061 | <0.01 |
Abbreviations: N, Number; IBS, irritable bowel syndrome; HR, hazard ratio; CI, confidence interval. a The cohort consisted of the infantile colic group who had experienced infantile colic from five weeks to four months of age and the control group without infantile colic histories during the same time period. b Weighted using inverse probability of exposure weighting based on the propensity score. The propensity score was estimated using multivariable logistic regression with 103 previous covariates, as defined in Table S2 in the Supplementary Materials. Participants in the reference group were weighted as (propensity score)/(1 − propensity score). This method produces a weighted pseudo-sample of participants in the reference group with the same distribution of measured covariates as the exposure group. c The tap water (reference) group consisted of children who mainly consumed formula powder prepared with tap water during the first 4 to 6 months of life. d The purified water group consisted of children who mainly consumed formula powder prepared with purified water during the first 4 to 6 months of life. e The hazard ratios were assessed using a Cox proportional hazards model to assess the risk of IBS according to the type of used water (tap water vs. purified water). f IBS was defined as more than two diagnoses with ICD-10 code K58.X (IBS) after the age of 4 years. g IBS-1 was defined as at least one diagnosis with ICD-10 code K58.X (IBS) and R10.X (abdominal pain), and an ICD-10 code K59.1 (functional diarrhea), K52.2 (allergic and dietetic gastroenteritis and colitis), K52.8 (other specific noninfective gastroenteritis), or K59.0 (constipation) after the age of four years. h IBS-2 was defined as two or more diagnoses of ICD-10 code K58.X (IBS) that were more than 6 months apart.
Figure 2Subgroup analysis (with stratification by sex) and sensitivity analysis (using different definitions of IBS) of the risk of IBS in children at the age of 4 to 6 years who consumed formula powder prepared with purified water rather than tap water (reference) during infancy. Irritable bowel syndrome as the main outcome was defined as more than twice the diagnosis of ICD-10 codes K58.X (irritable bowel syndrome) after 4 years of age. IBS-1 was defined as at least one diagnosis of ICD-10 code K58.X (IBS) and R10.X (abdominal pain) and at least one of ICD-10 code K59.1 (functional diarrhea), K52.2 (allergic and dietetic gastroenteritis and colitis), K52.8 (other specific noninfective gastroenteritis), or K59.0 (constipation) after the age of four years. IBS-2 was defined as two or more diagnoses of ICD-10 code K58.X (irritable bowel syndrome) with an interval of more than 6 months. This method produces a weighted pseudo-sample of participants in the reference group with the same distribution of measured covariates as the exposure group. Filled squares indicate hazard ratios, and straight lines indicate 95% confidence intervals. The asterisks indicate p < 0.05. The hazard ratios were assessed using a Cox proportional hazards model to examine the risk of IBS development in the cohort.